In the ovaries of cows, antral follicle growth is stimulated by the actions of gonadotropin. Basal release of gonadotropin-releasing hormone (GnRH) from the hypothalamus into the hypophyseal portal circulation maintains tonic gonadotropin secretion from the pituitary \[[@r1]\], resulting in follicular development and steroidogenesis in the ovaries \[[@r2]\]. In the last decade, kisspeptin, a peptide encoded by the *Kiss1* gene, has attracted attention as a key molecule in the regulation of GnRH/luteinizing hormone (LH) release in many mammalian species \[[@r3],[@r4],[@r5]\], including rodents, ruminants and primates. Several lines of evidence have shown that kisspeptin directly stimulates GnRH release via the kisspeptin receptor GPR54 (also described as Kiss1 receptor) \[[@r6],[@r7],[@r8]\]. The loss of *Kiss1* gene function in mice \[[@r9], [@r10]\] or *GPR54* in humans \[[@r11], [@r12]\] causes hypogonadotropic hypogonadism, suggesting that kisspeptin-GPR54 signaling plays a pivotal role in the regulation of reproductive functions. Indeed, local infusion of anti-kisspeptin antibody blocks the preovulatory \[[@r13]\] and estradiol-induced \[[@r14]\] LH surge in rats. Central infusion of a kisspeptin antagonist inhibits the estradiol-induced LH surge in sheep \[[@r15]\]. These reports strongly suggest that kisspeptin signaling is involved in the central mechanism regulating the GnRH/LH surge and ovulation.

Kisspeptin neurons could also be involved in the regulation of pulsatile GnRH release, which is essential in maintenance of the sensitivity of the pituitary gonadotroph to GnRH stimulation, and therefore follicular development and maturation. Repetitive administration of kisspeptin induces pulsatile GnRH/LH release in rats \[[@r16]\], sheep \[[@r17]\] and monkeys \[[@r18]\]. A GPR54 antagonist blocks endogenous GnRH/LH pulses in the above species \[[@r19], [@r20]\]. An electrophysiological study in goats demonstrated that the periodic increase in multiple-unit neuronal activity in the hypothalamic arcuate nucleus, where kisspeptin neurons reside, is temporally associated with LH pulses \[[@r21]\]. These studies suggest that kisspeptin neurons play a pivotal role in regulating pulsatile GnRH/LH release. However, it has not yet been shown whether activation of kisspeptin-GPR54 signaling has an effect on ovarian follicular growth and maturation.

The aim of the present study was to investigate whether follicular development is facilitated by peripheral administration of kisspeptin. Here, we used ovary-intact beef cows as a model, which allows monitoring of follicular dynamics in the same individual. We synthesized and used full-length bovine kisspeptin (Kp-53) to examine the effects of intravenous injection of the peptide on ovarian activity and gonadotropin secretory response in cows. We argued that if the stimulatory effects of Kp-53 administration on gonadal functions were confirmed in cows, then kisspeptin would be applicable as a novel drug for stimulating follicular development in veterinary therapy for farm animals.

Materials and Methods {#s1}
=====================

Animals
-------

All experiments were performed on 6- to 11-year-old Japanese Black beef cows (n = 5) weighing between 372 and 504 kg. All cows had three waves of follicular growth during the estrous cycle. Cows were maintained under natural conditions at the Field Science Center, Graduate School of Bioagricultural Sciences, Nagoya University, Japan. Cows were fed twice daily with grass silage or hay diet and had *ad lib* access to water and supplemental minerals. At least 1 day prior to the experiment, a 14-gauge catheter (length, 70 cm; CV Legaforce DX, Terumo, Tokyo, Japan) was placed into a jugular vein of the cows for drug injection and blood sampling. Some cows were used repetitively for the experiment. Two out of 5 cows were injected with all doses of Kp-53 and vehicle. Two cows were injected with vehicle and low or high doses of Kp-53, respectively. The remaining cow was injected with a high dose of Kp-53. All experiments were approved by the Committee for the Care and Use of Experimental Animals of the Graduate School of Bioagricultural Sciences, Nagoya University.

Reagents
--------

Bovine Kp-53 (cDNA sequence of bovine *KISS1* gene; GenBank accession number, AB466319) was prepared using the standard protocol for Fmoc-based peptide synthesis. Briefly, a protected peptide resin for Kp-53 was constructed on NovaSyn® TGR resin using HBTU/HOBt/DIEA. The resin was then treated with TFA/m-cresol/thioanisole/1,2-ethanedithiol/H~2~O (80:5:5:5:5) for 2 h. The crude product was purified by preparative HPLC to yield the expected peptide as a colorless powder.

Induction of estrus
-------------------

Ovaries were monitored by transrectal ultrasonography to identify whether the corpus luteum (CL) was present. If the presence of CL was confirmed, 25 mg of dinoprost (PGF~2α~, Veterinary Pronalgon®-F Injection; Pfizer Japan, Tokyo, Japan) was injected intramuscularly to regress the CL and induce estrus. After PGF~2α~ injection, CL regression and follicular growth, the behaviors of cows were observed every day until they showed standing estrus. The day of standing estrus was designated as the day of estrus (Day 0).

Bovine Kp-53 administration and blood sampling
----------------------------------------------

The effects of bovine Kp-53 on gonadotropin secretion were examined. Saline (n = 4) or bovine Kp-53 in 6 ml saline (0.2 nmol/kg, n = 3, or 2 nmol/kg, n = 4) was injected intravenously at 1200 h on Day 5 when the dominant follicle (DF) of the first follicular wave (first DF) had been selected. Doses of Kp-53 were selected in a pilot study because equivalent doses of kisspeptin C-terminal decapeptide (Kp-10) administration intravenously stimulated LH secretion in steers (data not shown). Whitlock *et al.* \[[@r22]\] also reported that bolus intravenous injection of Kp-10 at 0.1 nmol/kg stimulated LH secretion in ovariectomized cows treated with estradiol and progesterone. Blood samples (2 ml) were collected every 10 min for 8 h, starting at 4 h prior to injection. Plasma was separated and stored at --30 C until LH and FSH assays.

Ultrasonography
---------------

The effects of bovine Kp-53 on ovarian activity were examined. Ovarian antral follicles were monitored by transrectal ultrasonography using a 7.5-MHz transrectal linear probe (HS-1500, Honda Electronics, Toyohashi, Japan). Transrectal ultrasonography was performed once daily at 1800 h during one complete estrous cycle beginning on Day 0, and an additional observation was conducted at 0600 h from Day 5 (the day of injection) to Day 7. Ovaries were scanned in several planes, and ultrasonic images were recorded when the follicle size was greater than 5 mm in diameter at the widest axis of the follicle. The follicular diameter of each follicle was determined from the ultrasonographic images as an average of the widest diameter of the follicle and the length perpendicular to the widest diameter. The ruler function of Adobe Illustrator CS3 (Adobe Systems, San Jose, CA, USA) was used to measure the diameter from the ultrasonographic images, and the measured follicular diameter was calibrated to the actual size from the scale marked in each image. Ovulation was confirmed as the disappearance of an identified DF (≥ 9 mm) and the subsequent appearance of the CL.

Radioimmunoassays for LH and FSH
--------------------------------

Plasma LH concentrations were determined by a double-antibody radioimmunoassay (RIA) with a bovine LH RIA kit provided by the National Hormone and Peptide Program (NHPP; Baltimore, MD, USA). Highly purified bovine LH (AFP-11743) was used for iodination and cold standard. Rabbit anti-ovine LH serum (YM \#18) \[[@r23]\] was used as the primary antibody diluted 1:80,000 in RIA buffer \[50 mM phosphate buffer containing 100 mM NaCl and 0.1% sodium azide (pH 7.5)\] with 50 mM EDTA·2Na and 2% normal rabbit serum. Anti-rabbit gamma globulin goat serum (ARGG), developed in our laboratory, was used as the secondary antibody in RIA buffer with 50 mM EDTA·2Na and 3% polyethylene glycol. The bovine LH standard was diluted using RIA buffer with 1% bovine serum albumin (BSA) to a concentration between 0.0049 ng/100 µl and 1.25 ng/100 µl. Aliquots (50 µl) of unknown samples were diluted with 50 µl of RIA buffer with 1% BSA. Standard and unknown samples were mixed with 50 µl of anti-ovine LH solution and incubated at 4 C. After 48 h of incubation, ^125^I-labeled bovine LH (5,000 to 7,000 cpm/100 µl) in RIA buffer with 0.1% BSA was added to each tube and incubated for 48 h at 4 C, and ARGG solution was then added to each tube. After incubation for 48 h at 4 C, samples were centrifuged, and the radioactivity in the precipitates was counted with a gamma counter (ARC-1000M; Hitachi Aloka Medical, Tokyo, Japan). The lowest detectable LH concentration was 0.098 ng/ml in a 50-µl plasma sample. Intra- and inter-assay coefficients of variation were 10.4% at 0.56 ng/ml and 8.0% at 0.61 ng/ml, respectively.

Plasma FSH concentrations were determined by a double-antibody RIA with a bovine FSH RIA kit provided by the NHPP using rabbit anti-ovine FSH serum (NIDDK-anti-oFSH-1), and data were expressed in terms of AFP-5332B. The RIA procedure was performed as described above. The bovine FSH standard was diluted to a concentration between 0.0049 ng/100 µl and 1.25 ng/100 µl. The lowest detectable FSH concentration was 0.098 ng/ml in a 50-µl plasma sample. The intra- and inter-assay coefficients of variation were 11.8% at 0.56 ng/ml and 8.4% at 0.55 ng/ml, respectively.

Statistical analysis
--------------------

The actual follicle size in diameter at 0600 h on Day 5 (before injection) was compared between groups, and significant differences were determined by one-way ANOVA followed by Dunnett's post hoc comparison tests. Follicular growth of non-ovulated follicles after Kp-53 injection was expressed as the percentage of the mean follicular diameter before injection on Day 5. Significant differences between groups were determined by one-way ANOVA followed by Dunnett's post hoc comparison tests. The area under the curve (AUC) of each plasma LH and FSH profile was calculated with the trapezoidal rule during each 2-h sampling period before (--4 to --2 h and --2 to 0 h) and after (0 to 2 h and 2 to 4 h) injection. Significant differences between the values of just prior to injection (--2 to 0 h) and those of the other periods were determined by one-way ANOVA followed by Dunnett's test.

Results {#s2}
=======

Effects of intravenous injection of Kp-53 on ovarian activity
-------------------------------------------------------------

In 1 out of 4 cows treated with 2 nmol/kg of Kp-53, the first DF ovulated within 30 h of the injection (Supplementary Fig. S1A: on-line only). None of the animals treated with 0.2 nmol/kg of Kp-53 or vehicle ovulated after injection. In non-ovulated cows after injection of 2 nmol/kg Kp-53, follicular diameter increased ([Figs. 1](#fig_001){ref-type="fig"}A and[1](#fig_001){ref-type="fig"}BFig. 1.Effects of full-length kisspeptin (Kp-53) injection on ovarian follicles in adult beef cows. A: Representative ultrasound images of the ovaries in non-ovulatory cows treated with vehicle or Kp-53 (2 nmol/kg) at 0600 h on Day 5 (before injection) and at 1800 h on Day 7 (after injection). The day of standing estrus was designated as the day of estrus (Day 0). B: Two representative profiles of changes in follicle diameter in non-ovulatory cows treated with vehicle or Kp-53. The arrows indicate the time of intravenous injection of vehicle or Kp-53 (0.2 or 2 nmol/kg). C: Mean (± SEM) percent changes in follicle size in non-ovulatory cows after vehicle (*open columns*) or Kp-53 (*shaded columns*, 0.2 nmol/kg; *solid columns*, 2 nmol/kg) injection. Values are expressed as percent changes in the mean follicular diameter at 0600 h on Day 5. The numbers in each column indicate the number of animals used. \* P\<0.05 *vs.* vehicle injection (Dunnett's test).). Injection of Kp-53 at 0.2 nmol/kg resulted in a slight increase in follicular diameter. The follicular diameters at 0600 h on Day 5 (pretreatment) were 11.08 ± 0.40, 9.47 ± 0.32, and 9.10 ± 0.32 mm in the vehicle-, Kp-53 (0.2 nmol/kg)- and Kp-53 (2 nmol/kg)-treated groups, respectively. Because there were significant differences (P\<0.05) in follicle diameter between the vehicle- and Kp-53 (0.2 or 2 nmol/kg)-treated groups, follicular development in cows after Kp-53 injection was evaluated as the percentage of the pretreatment value ([Fig. 1C](#fig_001){ref-type="fig"}). Follicular growth accelerated in cows treated with 2 nmol/kg of Kp-53 after injection, and the size of the first DF was significantly increased (P\<0.05) at 1800 h on Day 5 and thereafter. The follicular size in animals injected with 0.2 nmol/kg of Kp-53 was also significantly increased (P\<0.05) at 1800 h on Day 6 and 0600 h on Day 7 but not at 1800 h on Day 7 (P=0.063).

Effects of intravenous injection of Kp-53 on gonadotropin secretion
-------------------------------------------------------------------

Treatment with 2 nmol/kg of Kp-53 resulted in a sustained increase in the plasma LH concentrations for a few hours after injection ([Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.Effects of full-length kisspeptin (Kp-53) injection on LH secretion in adult beef cows. A: Two representative profiles of plasma LH concentrations before and after intravenous injection of Kp-53. The arrows indicate the time of intravenous injection of vehicle or Kp-53 (0.2 or 2 nmol/kg). Blood samples were collected every 10 min for 8 h beginning 4 h before injection. B: Mean (± SEM) areas under the curve (AUCs) of LH profiles during every 2-h sampling period before (*opencolumns*) and after (*solid columns*) injection. \* P\<0.05 *vs.* the value just prior to injection (--2 to 0 h). and Supplementary Fig. S1B). Injection with 0.2 nmol/kg of Kp-53 had little or no effect on the plasma LH profiles. No injections at any dose of bovine Kp-53 changed the plasma FSH concentrations ([Fig. 3A](#fig_003){ref-type="fig"}Fig. 3.Effects of full-length kisspeptin (Kp-53) injection on FSH secretion in adult beef cows. A: Two representative profiles of plasma FSH concentrations before and after intravenous injection of Kp-53. The arrows indicate the time of intravenous injection of vehicle or Kp-53 (0.2 or 2 nmol/kg). Blood samples were collected every 10 min for 8 h beginning 4 h before injection. B: Mean (± SEM) areas under the curve (AUCs) of FSH profiles during every 2-h sampling period before (*opencolumns*) and after (*solid columns*) injection.). Statistical analysis revealed that the AUCs during the 2-h sampling periods (0 to 2 h and 2 to 4 h) for the LH secretory response to 2 nmol/kg of bovine Kp-53 treatment were significantly higher (P\<0.05) than the pretreatment value ([Fig. 2B](#fig_002){ref-type="fig"}). Animals treated with bovine Kp-53 at 0.2 nmol/kg showed no significant increase after injection. The AUC of FSH secretory response to Kp-53 did not show a significant change after peptide injection at any dose ([Fig. 3A and 3B](#fig_003){ref-type="fig"}). In 1 out of 4 cows whose first DF ovulated after 2 nmol/kg of Kp-53 treatment, the plasma LH concentrations increased to over 2 ng/ml at 2 h after the injection and were higher than those in the other groups (Supplementary Fig. S1B).

Discussion {#s3}
==========

The present study demonstrates that follicular development is facilitated in cows administered peripherally with full-length kisspeptin. Administration of 2 nmol/kg of Kp-53 induced elevation of LH concentrations from the basal level for up to 4 h, and the LH response to kisspeptin administration reflects the response of follicular growth after the kisspeptin injection. On the other hand, the size of the first DF increased after administration of 0.2 nmol/kg of Kp-53, although the concentrations of LH were not elevated after the injection. The follicular growth of the first DF in the latter case may be ascribed to normal growth in the DF because the follicular diameter at 0600 h on Day 5 (pretreatment) in Kp-53 (0.2 nmol/kg)-treated cows was significantly smaller than that in the vehicle-treated animals. The pretreatment size of the first DF in the Kp-53 (2 nmol/kg)-treated cows was equivalent to that in the Kp-53 (0.2 nmol/kg)-treated animals, suggesting that the further acceleration of follicular growth in Kp-53 (2 nmol/kg)-treated cows was due to the kisspeptin-induced LH secretion in the present study. A previous study had shown that a continuous Kp-10 infusion elicited a prolonged LH release and then estrogen secretion, followed by the preovulatory LH surge in acyclic ewes \[[@r24]\]. Although little FSH release was stimulated by kisspeptin treatment in the present study, it may be that follicle development is stimulated by the action of LH but not FSH after DF selection, as previously reported \[[@r25]\]. Our study also showed that administration of 2 nmol/kg of Kp-53 induced ovulation of the first DF in 1 out of 4 cows, but ovulation of the first DF did not occur in the rest of the cows. Although we do not know the reason for the different follicular response to the administration of a high dose of Kp-53, a possible mechanism of ovulation induction of the first DF after full-length kisspeptin treatment is higher concentrations of LH secretion occurring after administration (Supplementary Fig. S1B), which in turn causes ovulation (as previously reported in rats \[[@r26]\] and ewes \[[@r17]\]), than those in the other non-ovulated cows. Overall, it seems to be likely that, for clinical application in veterinary therapy, a single iv dose of Kp-53 between 0.2 to 2 nmol/kg is appropriate for stimulation of follicular growth without ovulation. Further, it might be advantageous to apply kisspeptin with infusions or repetitive injections for such purpose.

The action sites of peripherally injected kisspeptin could be the nerve terminals of GnRH neurons located in the median eminence (ME). Morphological evidence \[[@r27],[@r28],[@r29]\] has shown that kisspeptin neuronal fibers are closely associated with GnRH fibers in the ME. GnRH release is stimulated by kisspeptin treatment from ME tissue cultures *in vitro* \[[@r30]\]. Since the ME is one of the circumventricular organs outside the blood-brain barrier \[[@r31]\], peripherally injected kisspeptin would stimulate GnRH release by direct action on the GnRH neuronal terminals. There are other candidates for the action site of peripherally injected kisspeptin. *GPR54* mRNA and GPR54 protein are expressed in the brain as well as in the pituitary gland \[[@r32], [@r33]\] and in the ovaries \[[@r34], [@r35]\]; however, the physiological roles of GPR54 in these tissues are still unclear. In addition, some studies have reported that *in vitro* application of Kp-10 stimulates LH release from pituitary cells in rats \[[@r36]\], pigs \[[@r37]\], sheep \[[@r38]\], cattle \[[@r37]\] and primates \[[@r39]\]. However, the stimulatory effects of kisspeptin administration on LH secretion do not occur in hypothalamo-pituitary-disconnected ewes \[[@r38]\].

In the present study, FSH secretion was not induced after injections with Kp-53. There are 2 points of view concerning the reason for the lack of effect of Kp-53 on FSH secretion. First, synthesis and/or release of FSH could be affected by inhibitory factors, such as inhibin, from the DF in the ovary \[[@r40]\]. In this study, because Kp-53 was injected on Day 5 when a DF had been selected, inhibin might have been secreted from the larger follicle and blocked synthesis and/or release of FSH. Second, this may be ascribed to an insufficient release of GnRH induced by peripherally injected kisspeptin to stimulate FSH secretion. Navarro *et al*. \[[@r41]\] showed that the FSH secretory response to centrally injected kisspeptin is approximately 100-fold less sensitive than the LH response in male rats. The lower sensitivity of the FSH response to kisspeptin injection may be because kisspeptin induces a small amount of GnRH release and then LH secretion, and this injection may not be enough to induce FSH secretion. However, a previous study showed that peripheral injection of human Kp-10 induced FSH secretion in prepubertal cattle \[[@r42]\]. The reason why Kp-53 did not stimulate FSH secretion in the present study could be the differences in the animal model examined, since we used ovary-intact cows.

The present study suggests that kisspeptin or related peptides could be used as novel compounds controlling ovarian activity in domestic animals. The close relationship between follicle size at insemination and pregnancy success has been reported in beef cows \[[@r43]\]. Busch *et al*. \[[@r44]\] showed that progesterone secretion after GnRH-induced small follicle ovulation decreased compared with that after GnRH-induced large follicle ovulation or spontaneous ovulation. Nonpregnant cows had lower serum concentrations of progesterone beginning at 10 days post insemination compared with pregnant cows \[[@r44]\]. These reports suggest that induction of immature follicle ovulation by GnRH retains the risk of reduction in conception rate after artificial insemination. In the present study, follicular development of the first DF was facilitated in cows administered kisspeptin. Thus, kisspeptin may be useful in resolving the problems caused by GnRH-induced ovulation of small follicles. From this standpoint, more potent kisspeptin derivatives are required for practical use in cows to stimulate gonadotropin secretion and follicular development. It has been demonstrated that the kisspeptin C-terminal pentapeptide is the pharmacophore that activates GPR54 \[[@r45]\] and that the pentapeptide derivatives have potent agonistic activity \[[@r46]\]. Recently, it was shown that novel GPR54 agonists stimulated LH secretion when the pentapeptide derivatives were injected locally into the preoptic area where GnRH neurons are located in rats \[[@r47]\].

In conclusion, we found that follicular development of the first DF accelerated in cows treated peripherally with full-length bovine kisspeptin. This effect was mediated by LH release induced by kisspeptin injection. Full-length kisspeptin is also capable of inducing ovulation. Thus, kisspeptin or related peptides might be advantageous for potential usage as novel drugs for stimulating follicular development and ovulation.
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